Fredun Pharmaceuticals Hits New 52-Week High at Rs.1979.95

Strong Momentum Drives Stock to Record Levels

On 1 Dec 2025, Fredun Pharmaceuticals demonstrated robust momentum, opening with a gap up of 2.94% and reaching an intraday peak at Rs.1979.95. This price represents the highest level the stock has attained in the past year, surpassing previous resistance points and setting an all-time high. The stock outperformed its sector by 2.33% on the day, reflecting a strong relative performance amid a broadly positive market backdrop.

The stock has recorded gains for four consecutive trading sessions, accumulating a return of 9.79% during this period. This sustained upward movement has been supported by the stock trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a consistent positive trend across multiple timeframes.

Market Context and Sector Performance

The broader market environment has also been conducive to Fredun Pharmaceuticals’ rally. The Sensex opened higher at 86,065.92 points, gaining 359.25 points or 0.42%, and was trading near its own 52-week high, just 0.21% shy of 86,055.86. The index has been on a three-week consecutive rise, accumulating a 1.55% gain, with small caps leading the charge, as evidenced by the BSE Small Cap index advancing 0.4% on the day.

This positive market sentiment, combined with sector-specific factors, has provided a favourable backdrop for Fredun Pharmaceuticals to extend its gains and reach new price heights.

Financial Performance Underpinning the Rally

Fredun Pharmaceuticals’ recent price performance is supported by its financial results, which reflect strong growth across key metrics. The company’s net sales have shown an annual growth rate of 39.73%, while operating profit has expanded at a rate of 55.03%. In the latest quarter, net sales stood at Rs.145.30 crores, representing a 35.35% increase compared to previous periods.

Operating profit before depreciation, interest, and taxes (PBDIT) reached Rs.22.35 crores, the highest recorded to date. The operating profit to interest ratio for the quarter was 2.89 times, indicating a comfortable coverage of interest expenses by operating earnings.

Net profit growth has been particularly notable, with a 127.87% rise reported in the most recent quarter. This strong profitability trend has been consistent, with the company declaring positive results for six consecutive quarters, underscoring a sustained improvement in financial health.

Valuation and Return Metrics

Fredun Pharmaceuticals exhibits an attractive return on capital employed (ROCE) of 20.2%, reflecting efficient utilisation of capital resources. The enterprise value to capital employed ratio stands at 3.4, suggesting a valuation level that compares favourably with peers in the Pharmaceuticals & Biotechnology sector.

Over the past year, the stock has delivered a total return of 164.51%, significantly outpacing the Sensex’s 7.61% return over the same period. Profit growth over the last year has been recorded at 63.5%, highlighting the company’s ability to convert revenue gains into bottom-line expansion. The price-to-earnings-to-growth (PEG) ratio is 0.5, indicating a valuation that is reasonable relative to earnings growth.

Price Range and Historical Context

The stock’s 52-week low price was Rs.635, illustrating a substantial price appreciation over the past year. This wide price range highlights the significant value creation that has occurred, with the current price near Rs.1979.95 representing a more than threefold increase from the low point.

Fredun Pharmaceuticals’ performance has also outpaced the BSE500 index over the last three years, one year, and three months, reflecting consistent market-beating returns in both the near and longer term.

Market Participation and Shareholding

Despite the company’s size and performance, domestic mutual funds currently hold no stake in Fredun Pharmaceuticals. This absence of mutual fund participation may reflect a cautious stance or differing views on valuation and business prospects within institutional circles.

Nonetheless, the stock’s recent price action and financial results provide a clear indication of its current standing within the Pharmaceuticals & Biotechnology sector.

Summary

Fredun Pharmaceuticals’ achievement of a new 52-week high at Rs.1979.95 marks a key milestone in its market journey. Supported by strong financial growth, consistent profitability, and favourable market conditions, the stock has demonstrated significant momentum. Trading above all major moving averages and outperforming its sector peers, Fredun Pharmaceuticals continues to command attention within its industry segment.

Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →